Shukra [SHUKRAPHAR] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Shukra Pharmaceuticals Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Shukra Pharmaceuticals Ltd. wins in 9 metrics, Divi's Laboratories Ltd. wins in 11 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Shukra Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 770.20 67.11 Divi's Laboratories Ltd.
Price-to-Book Ratio 22.86 10.82 Divi's Laboratories Ltd.
Debt-to-Equity Ratio 5.71 0.58 Divi's Laboratories Ltd.
PEG Ratio 1.39 4.63 Shukra Pharmaceuticals Ltd.
EV/EBITDA 34.62 48.63 Shukra Pharmaceuticals Ltd.
Profit Margin (TTM) 45.16% 24.04% Shukra Pharmaceuticals Ltd.
Operating Margin (TTM) 67.87% 29.65% Shukra Pharmaceuticals Ltd.
EBITDA Margin (TTM) 67.87% 29.65% Shukra Pharmaceuticals Ltd.
Return on Equity 15.24% 14.64% Shukra Pharmaceuticals Ltd.
Return on Assets (TTM) 11.04% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $51.75M $2.15B Divi's Laboratories Ltd.
Dividend Yield 3.20% 0.91% Shukra Pharmaceuticals Ltd.
1-Year Return 104.99% -0.43% Shukra Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 21.46 16.18 Divi's Laboratories Ltd.
Enterprise Value $13.61B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 21.08 15.86 Divi's Laboratories Ltd.
Gross Profit Margin (TTM) 81.77% 63.71% Shukra Pharmaceuticals Ltd.
Revenue per Share (TTM) $1 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $-0.20 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.94 0.19 Divi's Laboratories Ltd.

Shukra Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

SHUKRAPHAR
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Shukra Pharmaceuticals Ltd.3.57%-2.60%-1.15%-23.64%-42.21%-44.86%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Shukra Pharmaceuticals Ltd.104.99%517.94%1,925.00%2,071.74%707.82%707.82%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Shukra Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricSHUKRAPHARDIVISLAB
Market Information
Market Cap i₹13.91B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i458,425253,443
90 Day Avg. Volume i341,812283,911
Last Close₹31.04₹6,608.50
52 Week Range₹12.97 - ₹65.26₹5,636.50 - ₹7,071.50
% from 52W High-52.44%-6.55%
All-Time High₹65.26 (Dec 19, 2025)₹7,071.50 (Jul 08, 2025)
% from All-Time High-52.44%-6.55%
Growth Metrics
Quarterly Revenue Growth2.45%0.12%
Quarterly Earnings Growth5.44%-0.01%
Financial Health
Profit Margin (TTM) i0.45%0.24%
Operating Margin (TTM) i0.68%0.30%
Return on Equity (TTM) i0.15%0.15%
Debt to Equity (MRQ) i5.710.58
Cash & Liquidity
Book Value per Share (MRQ)₹1.38₹580.95
Cash per Share (MRQ)₹0.31₹122.95
Operating Cash Flow (TTM) i₹66.80M₹19.67B
Levered Free Cash Flow (TTM) i₹95.75M₹21.91B
Dividends
Last 12-Month Dividend Yield i3.20%0.91%
Last 12-Month Dividend i₹1.02₹60.00

Valuation & Enterprise Metrics Analysis: Shukra Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricSHUKRAPHAR (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i770.2067.11
Forward P/E iN/A53.75
PEG Ratio i1.394.63
Price to Sales (TTM) i21.4616.18
Price to Book (MRQ) i22.8610.82
Market Capitalization
Market Capitalization i₹13.91B₹1.69T
Enterprise Value i₹13.61B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i21.0815.86
Enterprise to EBITDA i34.6248.63
Risk & Other Metrics
Beta i0.940.19
Book Value per Share (MRQ) i₹1.38₹580.95

Financial Statements Comparison: Shukra Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSHUKRAPHAR (2025)DIVISLAB (2025)
Revenue/Sales i325.87M93.25B
Cost of Goods Sold i81.12M38.70B
COGS % of Revenue i24.9%41.5%
Gross Profit i244.76M54.55B
Gross Margin i75.1%58.5%
Research & Development i1.66M270.00M
Operating Income (EBIT) i97.25M25.71B
Operating Margin i29.8%27.6%
EBITDA i168.63M33.19B
EBITDA Margin i51.7%35.6%
Pre-Tax Income i133.37M29.16B
Pre-Tax Income % of Revenue i40.9%31.3%
Income Tax i37.61M7.25B
Income Tax % of Revenue i11.5%7.8%
Net Income (Profit) i95.75M21.91B
Profit Margin i29.4%23.5%

Balance Sheet & Liquidity Metrics

MetricSHUKRAPHAR (2025)DIVISLAB (2025)
Cash & Equivalents i121.18M4.15B
Total Current Assets i654.27M100.81B
Total Current Assets % of Revenue i200.8%108.1%
Total Current Liabilities i172.84M14.52B
Total Current Liabilities % of Revenue i53.0%15.6%
Long-Term Debt i31.13M20.00M
Long-Term Debt % of Revenue i9.6%0.0%
Total Shareholders Equity i628.36M149.69B
Retained Earnings i143.00M134.00B
Retained Earnings % of Revenue i43.9%143.7%
Property, Plant & Equipment i193.97M3.19B

Cash Flow Statement Comparison

MetricSHUKRAPHAR (2025)DIVISLAB (2025)
Operating Cash Flow i66.80M19.67B
Operating Cash Flow % of Revenue i20.5%21.1%
Capital Expenditures i-27.43M-14.38B
Free Cash Flow i51.75M2.15B
FCF Margin i15.9%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSHUKRAPHARDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i437.88M265.47M
Float Shares i46.25M117.72M
% Held by Insiders i89.33%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i10.67%19.31%

Dividend Analysis & Yield Comparison: Shukra Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricSHUKRAPHARDIVISLAB
Last 12-Month Dividend i₹1.02₹60.00
Last 12-Month Dividend Yield i3.20%0.91%
3-Year Avg Annual Dividend i₹0.35₹50.00
3-Year Avg Dividend Yield i3.91%0.70%
3-Year Total Dividends i₹1.05₹150.00
Ex-Dividend DateSep 23, 2025Jul 25, 2025